Investor
SECTOR GAMMA AS
CIK 0001475373 · filed 2026-05-07 · SEC filing
13F book
$423.5M
Positions
42
11 new · 5 sold
Largest name
11.9%
Bristol-Myers Squibb Co
Est. mark
−$6.44M
Price effect on 31 names still held. Flow −$8.78M.
| Name | Ticker | Shares | Value | Weight | Est. mark | Change |
|---|---|---|---|---|---|---|
| Bristol-Myers Squibb Co | — | 827.9K | $50.2M | 11.9% | $5.01M | Added$9.98M |
| Merck & Co., Inc. | MRK | 260.3K | $31.3M | 7.4% | $3.91M | Cut−$6.96M |
| Pfizer Inc | PFE | 1.09M | $30.6M | 7.2% | $2.73M | Added$9.24M |
| Medtronic Plc | MDT | 280.7K | $24.3M | 5.7% | −$2.54M | Added−$1.58M |
| Incyte Corp | INCY | 200.5K | $18.9M | 4.5% | −$932.4K | Cut−$2.74M |
| Amgen Inc | AMGN | 47.2K | $16.6M | 3.9% | $1.16M | Cut−$3.36M |
| Biogen Inc. | BIIB | 90.1K | $16.5M | 3.9% | $627.4K | Added$1.47M |
| Zimmer Biomet Holdings, Inc. | ZBH | 155.8K | $14.1M | 3.3% | $66.2K | Added$2.18M |
| Biomarin Pharmaceutical Inc | BMRN | 239.9K | $13.6M | 3.2% | −$583.6K | Added$1.76M |
| Becton Dickinson & Co | BDX | 82.6K | $13M | 3.1% | −$3.04M | Cut−$12.7M |
| Elevance Health Inc Formerly | — | 44K | $12.9M | 3.0% | −$1.88M | Added$1.46M |
| Ionis Pharmaceuticals Inc | IONS | 169.5K | $12.7M | 3.0% | −$681.3K | Cut−$1.91M |
| Cardinal Health Inc | CAH | 54.9K | $11.6M | 2.7% | $319K | Cut−$1.13M |
| Unitedhealth Group Inc | UNH | 36.4K | $9.86M | 2.3% | — | New |
| Cvs Health Corp | CVS | 135.3K | $9.72M | 2.3% | −$1.02M | Cut−$4.37M |
| Bruker Corp | — | 254K | $9.17M | 2.2% | −$2.79M | Cut−$2.82M |
| Ge Healthcare Technologies I | — | 126.4K | $9M | 2.1% | −$1.24M | Added−$383.8K |
| Abbott Labs | ABT | 87.5K | $8.99M | 2.1% | — | New |
| Gilead Sciences, Inc. | GILD | 53.2K | $7.42M | 1.8% | $885.5K | Cut−$14.2M |
| Lantheus Hldgs Inc | — | 93.3K | $7.08M | 1.7% | $868.1K | Cut$836.2K |
| Iqvia Hldgs Inc | — | 40.2K | $6.86M | 1.6% | — | New |
| Syndax Pharmaceuticals Inc | SNDX | 286K | $6.68M | 1.6% | $592.3K | Added$1.39M |
| Bio Rad Labs Inc | — | 23.8K | $6.62M | 1.6% | −$575.7K | Held |
| Qiagen Nv Ord Shares | — | 162.4K | $6.5M | 1.5% | — | New |
| Avantor, Inc. | AVTR | 695.4K | $5.45M | 1.3% | −$2.52M | Held |
| Centene Corp Del | — | 162.4K | $5.32M | 1.3% | −$1.37M | Cut−$5.3M |
| Tandem Diabetes Care Inc | TNDM | 267.1K | $5.12M | 1.2% | −$750.5K | Held |
| Ptc Therapeutics, Inc. | PTCT | 75K | $5.11M | 1.2% | −$484.9K | Added$406.1K |
| Labcorp Holdings Inc. | LH | 19K | $5.07M | 1.2% | $303K | Cut−$1.7M |
| Ascendis Pharma A/S | ASND | 21.3K | $4.87M | 1.2% | $252.6K | Added$1.4M |
| Edwards Lifesciences Corp | EW | 60.4K | $4.84M | 1.1% | −$312.3K | Cut−$3.38M |
| Dexcom Inc | DXCM | 56.1K | $3.52M | 0.8% | −$200.4K | Cut−$1.53M |
| Crinetics Pharmaceuticals In | — | 94.2K | $3.42M | 0.8% | −$963.6K | Cut−$1.93M |
| Kura Oncology, Inc. | KURA | 411.8K | $3.35M | 0.8% | −$930.7K | Cut−$1.39M |
| Humana Inc | HUM | 19.2K | $3.33M | 0.8% | — | New |
| BridgeBio Pharma, Inc. | BBIO | 44.3K | $3.29M | 0.8% | — | New |
| Iovance Biotherapeutics, Inc. | IOVA | 900K | $3.16M | 0.7% | — | New |
| Denali Therapeutics Inc. | DNLI | 162.7K | $3.12M | 0.7% | — | New |
| Ardelyx, Inc. | ARDX | 516.1K | $3.09M | 0.7% | — | New |
| Cogent Biosciences, Inc. | COGT | 80K | $3.08M | 0.7% | — | New |
| Organon & Co. | OGN | 376K | $2.25M | 0.5% | −$354K | Added$101.1K |
| Arrowhead Pharmaceuticals In | — | 30K | $1.88M | 0.4% | — | New |
Positions as of Q1 2026. 13F filings arrive up to 45 days after quarter-end and omit shorts. Values are quarter-end marks, as filed. Estimated mark is the price effect on shares still held — not realized P&L or investment advice.